Monoclonal Antibodies for Cancer Immunotherapy Publisher



Zarnani AH^{1, 2} ; Jafari D^{3, 4} ; Bozorgmehr M² ; Shabani M⁵ ; Barzegaryarmohammadi L⁵ ; Ghaemimanesh F⁵ ; Jedditehrani M⁵
Source: Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition Published:2020

Abstract

Over the past few decades, monoclonal antibodies (mAbs), as potent antitumor tools, have remarkably advanced the cancer therapy, because of their target specificity as well as little off-target effects in comparison to most small molecule drugs. The use of antibody engineering methods has made it possible for investigators to develop antibody structures with improved efficacy for application in clinical practice. The development of efficacious therapeutic mAbs entails gaining in-depth knowledge about factors including antibody structure and function, the properties of an ideal tumor antigen, the advantages of employing combinational therapies, and the limitations of antibody-based modalities. This chapter concentrates on mAbs as versatile platforms for cancer immunotherapy. © Springer Nature Switzerland AG 2015, 2021. All rights reserved.